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Safety and Effectiveness of Central Venous Catheterization  
in Patients with Cancer: Prospective Observational Study
This study investigated the safety and effectiveness of each type of central venous 
catheters (CVC) in patients with cancer. We prospectively enrolled patients with cancer 
who underwent catherization involving a subclavian venous catheter (SVC), peripherally 
inserted central venous catheter (PICC), or chemo-port (CP) in our department. From 
March 2007 to March 2009, 116 patients underwent 179 episodes of catherization. A SVC 
was inserted most frequently (46.4%). Fifty-four complications occurred (30.1%): 
infection in 23 cases, malpositioning or migration of the tip in 18 cases, thrombosis in 
eight cases, and bleeding in five cases. Malpositioning or migration of the tip occurred 
more frequently with a PICC (P<0.001); infection occurred more often with a tunneled 
catheter (P=0.028) and was observed more often in young patients (P=0.023). The 
catheter life span was longer for patients with solid cancer (P=0.002) than for those with 
hematologic cancer, with a CP (P<0.001) than a PICC or SVC, and for an indwelling 
catheter with image guidance (P=0.014) than a blind procedure. In conclusion, CP is an 
effective tool for long term use and the fixation of tip is important for the management of 
PICC. 
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INTRODUCTION
The development of increasingly complex treatment regimens 
for patients with advanced malignancies has led to a greater re-
liance on a variety of intravenous delivery systems. Patients who 
have cancer usually require repeated venous punctures for treat-
ment monitoring, application of chemotherapy, or blood trans-
fusions. Therefore, central venous catheters (CVCs) and implant-
able port systems have substantially facilitated the problem of 
vascular access. However, CVCs have inevitable problems such 
as insertion-related and long-term complications despite pro-
viding benefits to patients. The incidence of CVC-related com-
plications is relatively high based on data from a study commis-
sioned by the Food and Drug Administration in the 1990s, which 
showed a 10-25% complication rate and 10% morbidity (1). In-
sertion-related complications have dramatically decreased since 
the use of ultrasound guidance (USG), although one report de-
scribed negative effects of USG (2). Major complications related 
to CVCs include infection and thrombosis (3, 4). Various man-
agement strategies have been recommended to prevent and treat 
infection and thrombosis (5), and CVC outcomes have improved 
considerably. Along with improvements in insertion technique 
and CVC management, improvements have been made in cath-
eter design and materials, which have contributed to reducing 
CVC-related complications. To date, reports have dealt with the 
management guidelines for CVCs in patients with cancer (5-7), 
but institutional catheter implantation and maintenance guide-
lines tend to vary substantially. Furthermore, various kinds of 
catheters are available, each with its own strengths and weak-
ness. Physicians must consider various factors such as catheter 
duration, technique, compliance, complications, cost, and effi-
cacy to decide which catheter is best for optimal access to each 
patient. However, no evidence-based guide has been established 
to select the most appropriate vascular access device for each 
clinical situation, notwithstanding the broad range of vascular 
access devices available. In Korea, there were few studies for the 
subtype of CVCs (8, 9); however there was no report for the pro-
spectively comprehensive study of CVCs in cancer patients. 
Therefore, we conducted this study prospectively to investigate 
the safety, efficacy, and complication rate of the various kinds 
of CVCs in patients with cancer, to provide the guidance for the 
central venous catheterization in cancer patients. 
 
MATERIALS AND METHODS
Patients and CVCs 
We prospectively enrolled cancer patients who were admitted to 
our department, and underwent catheterization for various pur-
poses. The CVCs included a subclavian venous catheter (SVC), a 
peripherally inserted central venous catheter (PICC), or a chemo-Kim HJ, et al.  •  Central Venous Catheterization in Patients with Cancer
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port (CP). The CVCs were categorized as tunneled catheters, 
CPs, and non-tunneled catheters, SVCs and PICCs, and the phy-
sician determined which CVC was appropriate. Indwelling of 
the catheter was performed by an expert interventional radiolo-
gist with radiological guidance, or it was performed at bedside 
with a blind approach. All operators wore aseptic gowns, masks, 
gloves, and all patients received a dressing with aseptic drapes. 
The SVCs had double or triple lumens and were permitted only 
for hospitalized patients. The PICC was inserted through the an-
tecubital, basilic, brachial, or cephalic vein with USG and was 
used for both inpatients and outpatients. The PICC usually had 
a single lumen (5 Fr) and was made of silicone or second-/third-
generation polyurethane. The CP was a totally implanted port, 
had Dacron anchoring cuffs with a reservoir and a single lumen, 
and was used for both inpatients and outpatients. CP insertion 
was performed by an expert interventional radiologist in the 
angiography room with fluoroscopic guidance. 
Prophylaxis and maintenance management 
No patient was given prophylactic antibiotics or anticoagulation 
drugs for infection or thrombosis. All patients received a closed 
dressing with Betadine on the catheter insertion site every 3 days. 
A saline flush (once daily) or heparin flush (once weekly, 10 mL) 
was performed for the hospitalized patients. Patients who had 
completed scheduled therapy with a CP received a heparin flush 
every 3 months. 
Definitions of complications and management for 
complications
We checked for any immediate- and late-onset complications. A 
catheter-related infection occurred when an infection was doc-
umented from a catheter tip culture or when a differential quan-
titative blood culture indicated the differential time to positivity 
(DTTP). We removed the central catheter when we detected a 
complicated catheter infection, such as a fungal or Gram-nega-
tive infection; however, we used salvage therapy, such as antibi-
otic locking therapy, for uncomplicated infections with tunneled 
catheters. All patients with catheter-related infections were ad-
ministered systemic antibiotics for at least 2 weeks, either intra-
venously or orally. Catheter-related thrombosis was suspected 
when the flow rate slowed or it was impossible to backflush the 
catheter, and a confirmational study was conducted using Dop-
pler USG or venography. However, all patients who had throm-
bosis symptoms, with or without a confirming test, were includ-
ed as having thrombotic complications. When we suspected a 
catheter thrombus, we injected 5,000 IU of heparin or urokinase 
into the catheter. If this failed, we removed the catheter.
Statistical analysis
The primary endpoint was the complication rate. The secondary 
endpoints were catheter life span, catheter maintenance success 
rate, and factors affecting complications or the catheter life span. 
The catheter life span was calculated from the insertion date to 
the removal date and was assessed using the Kaplan–Meier meth-
od. The catheter maintenance success rate was defined by pa-
tients who maintained their catheters for the duration of the in-
tended purpose such as the completion of therapy, discharge, 
or death. We used the chi-square test for categorical variables 
and the independent t-test for continuous variables to analyze 
the patient characteristics. To analyze the factors affecting the 
complication rate, we used the chi-square test or Fisher’s exact 
test with a cross analysis. To analyze the factors affecting cathe-
ter life span, we used the Kaplan–Meier method and log-rank 
test for the univariate analysis and the Cox’s proportional haz-
ard regression model for the multivariate analysis. All tests were 
two-sided. 
Ethics statement 
This study was approved by the Institutional Review Board of 
Soonchunhyang University Bucheon Hospital (Approval No. 07-
42). After the protocol was approved, written informed consent 
was obtained from all patients before the entry of the study. All 
data collected from this study were kept confidential. 
RESULTS 
Patients and CVC characteristics 
From March 2007 to March 2009, 116 patients underwent 179 
catherization episodes. The median age was 61 yr (range, 20-80 
yr). The median follow-up duration was 344 days (range, 64-767 
days). The male to female ratio was 60:56, and 76 patients had 
solid malignancies, while 40 patients had hematologic malig-
nancies. The median number of catheter insertions per patient 
was one (range, 1-4). A SVC was inserted most frequently (83 
cases, 46.4%), followed by a CP (72 cases, 40.2%) and a PICC (24 
cases, 13.4%). Most catheter insertions (170 cases, 95.0%) were 
performed in the angiography room with USG or fluoroscopic 
guidance. Blood product transfusion occurred in 136 cases 
(76.0%) and total parenteral nutrition (TPN) in 85 cases (47.5%) 
(Tables 1, 2). 
Complications and factors affecting the complications 
Fifty-four complications (30.1%) occurred in the 179 catheter-
ization episodes. The most frequently documented complica-
tion was infection in 23 cases (12.8%), followed by malposition-
Table 1. Patient characteristics 
Parameters Patients (N=116)
Age, years, median (range)    61 (20-80)
Male (%) 60 (51.7)
Solid malignancy, No. (%) 76 (65.5)
No. of catheter insertions, median (range) 1 (1-4)Kim HJ, et al.  •  Central Venous Catheterization in Patients with Cancer
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ing or migration of the tip in 18 cases (10.1%), thrombosis in eight 
cases (4.5%), and minor or major bleeding at the insertion site 
in five cases (2.8%). SVCs had significantly fewer complications 
than PICCs or CPs (18.1% vs 50% vs 34.7%). The incidence of in-
fection was not different among disease type, gender, procedure 
technique (image guidance vs blind approach), transfusion, or 
TPN. However, infection occurred more in CPs than SVCs or 
PICCs (P=0.028). Additionally, an infection occurred more fre-
quently in younger patients than older patients (P=0.023). Mal-
positioning or migration of the tip occurred more frequently with 
a PICC (P<0.001) than a SVC or a CP (33.3% vs 7.2% vs 5.6%). The 
incidence of thrombosis or bleeding was not different among 
gender, disease type, catheter type, procedural technique (im-
age guidance vs blind approach), transfusion, or TPN (Table 3). 
Catheter maintenance success rate and causes for removal 
The catheter maintenance success rate was evaluable in 123 
cases. The others were not due to a failure to complete therapy 
(38 cases), transfer to another hospital (15 cases), or not appli-
cable (3 cases). Catheter maintenance was successful in 79 cas-
es (64.2%) and removal of the catheter before the intended time 
(therapy completion, discharge, or death) occurred in 44 cases 
(35.8%). The catheter maintenance success rate was 72.7%. In-
fection (41.9%) or migration of the tip occurred in 41.9% of cases, 
followed by thrombosis in six cases and bleeding in one case. 
Catheter life span and factors affecting catheter life span 
The median catheter life span was 45 days (95% confidence in-
terval [CI], 32.3-57.6). The catheter life span was longer in pa-
tients with solid cancer (median days, 64 vs 32, P=0.002) than 
those with hematologic cancer. Furthermore, life span was lon-
ger for CPs (269 vs 37 vs 21 days, P<0.001) than PICCs or SVCs, 
and for indwelling catheters inserted with image guidance (45 
vs 14 days, P=0.014) rather than a blind procedure. The multi-
variate analysis revealed that solid cancer and CP were signifi-
cant factors for catheter life span compared to hematologic 
cancer or other catheter types. However, catheter life span was 
not different among gender, age (<60 vs ≥60 yr), or transfusion 
(Table 4, Fig. 1).
DISCUSSION 
CVCs have a paramount role throughout the management of 
an oncology patient, as they are needed in the initial phases for 
surgery or chemotherapy, in the advanced stage for chronic treat-
ment, and in the last stage for palliative measures. The insertion 
of a CVC may be the initial therapeutic step in some patients who 
have advanced cancer. Physicians must determine the individ-
ualized catheter type by considering various factors such as cath-
eter duration, technique, compliance, complications, cost, and 
efficacy. CVCs are classified by tip position, technical features, 
or materials. They can be classified in terms of short-term, me-
Table 2. Catheter characteristics 
Variables Total catheters (N=179)
Subtype, No. (%)
   SVC
   CP
   PICC 
  83 (46.4)
  72 (40.2)
  24 (13.4)
Insertion Technique, No. (%)
   Image guidance vs blind approach
170 (95.0) vs 9 (5.0)
Transfusion, No. (%) 136 (76.0)
TPN, No. (%)   85 (47.5)
Complication, No. (%)
  Infection 
  Thrombosis
  Malpositioning and migration
  Bleeding 
  54 (30.1)
  23 (12.8)
  8 (4.5)
  18 (10.1)
  5 (2.8)
Catheter life span, days, median (95% CI)  45 days (95% CI, 32.3-57.6)
Causes for catheter removal. No. (%) 
   Infection 
   Thrombosis
   Malpositioning and migration 
   Bleeding
  18 (41.9)
    6 (14.0)
  18 (41.9)
  1 (2.2)
SVC, subclavian venous catheter; CP, chemo-port; PICC, peripherally inserted central 
venous catheter; TPN, total parenteral nutrition. 
Table 3. Factors affecting the complication rate 
Variables
Infection  Thrombosis Bleeding
Migration  
of tip 
P value*
Disease type 
   (solid ca vs hematologic ca)
0.818  0.214  0.650 0.615
Catheter type 
   (CP vs SVC vs PICC)
0.028  0.107  0.175 <0.001
Gender (Male vs. Female) 0.475 0.074  0.250 0.116
Age (<60 vs ≥60 yr)      0.023 0.563 0.212 0.205
Procedural technique 
   (blind vs image guidance) 
0.873  0.506  0.602 0.116
Transfusion (yes vs no) 0.187 0.947  0.831 0.850
TPN (yes vs no) 0.503 0.884 0.371 0.822
*This values were analyzed by chi-square test.
Ca, cancer; CP, chemo-port; SVC, subclavian venous catheter; PICC, peripherally 
inserted central venous catheter; TPN, total parenteral nutrition.
Table 4. Factors affecting catheter life span
Factors
Univariate 
analysis 
Multivariate 
analysis 
P value*
Gender (male vs female) 0.578  -
Age (<60 vs ≥60 yr) 0.318  -
Disease type (solid ca vs hematologic ca) 0.002  0.027
Catheter type (CP vs SVC vs PICC) <0.001  <0.001
Procedural technique (blind vs image guidance)   0.014 0.067
Transfusion (yes vs no) 0.170 -
*This values were analyzed by Kaplan–Meier method and log-rank test for the uni-
variate analysis and the Cox’s proportional hazard regression model for the multivariate 
analysis.
Ca, cancer; CP, chemo-port; SVC, subclavian venous catheter; PICC, peripherally in-
serted central venous catheter.Kim HJ, et al.  •  Central Venous Catheterization in Patients with Cancer
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dium-term, or long-term access. Because SVCs are a non-tun-
neled catheter, the expected duration was generally short, and 
they have a known disadvantage of infection. The PICC is also a 
non-tunneled catheter and is useful for a relatively longer dura-
tion. The CP is a tunneled catheter and is useful for the long term. 
Tunneled catheters and PICCs (1, 10) are held to have lower in-
fection rates, but no randomized controlled trials have demon-
strated this contention to date (11). Additionally, thrombosis 
occurs more often with a PICC than other catheters due to the 
influence of multifactorial phenomena (12). 
  Based on these previous results and recommendations, we 
chose a particular type of catheter for each patient. However, 
some results differed from previous studies regarding the com-
plication rate and catheter life span. Catheter-related infection 
occurred in 12.8%, was observed more in CPs than others, and 
was not significantly related with disease type, gender, procedur-
al technique, transfusion, or TPN. The CP is a totally implanted 
tunnel catheter and requires needling through a subcutaneous 
tract, which presents the risk for a skin floral infection, especial-
ly in immunocompromised patients. CPs were used in patients 
with a solid malignancy, including those who experienced pro-
longed chemotherapy-related neutropenia and in patients with 
a hematologic malignancy. This trend may affect the CP-related 
high risk of infection due to the increased incidence of neutro-
penia in patients with a CP (13, 14). Furthermore, we found that 
a catheter-related infection was more frequent in young patients 
than in the elderly, which is consistent with the report of Samaras 
et al. (15). In the study, young patients had more hematologic 
cancer than solid cancer, and hematologic cancer was a risk fac-
tor for infection. However, the type of disease was not a signifi-
cant factor for infection in our results, and no relationship was 
observed between age and disease type. Therefore, we cannot 
explain why age was a risk factor for infection, but we suggest 
that young patients may have received more intensive therapy 
than elders, and this factor may have contributed to the increased 
infection risk and increased incidence of neutropenia. In five 
cases, CVC-related infections were treatable with systemic anti-
microbials and antibiotic locking therapy without removing the 
catheter; however, most (18 cases, 78%) resulted in catheter re-
moval. Therefore, to maintain a long-duration CP, we should 
consider factors such as expected prolonged neutropenia or age 
and the need for more careful nursing, especially for needling. 
Further study is warranted for preventive strategies such as skin 
antisepsis, maximum sterile barriers, use of antimicrobial cath-
eters, and antimicrobial catheter lock solutions (16, 17). 
  The incidence of thrombosis was 4.5% in our study, which 
was relatively low despite not using prophylactic anticoagula-
tion. Of course, this may be an underestimate because asymp-
tomatic patients were excluded. Debate about prophylactic an-
ticoagulation has been ongoing. Prophylactic low-dose warfarin 
(1 mg/d) (18) and low-molecular-weight heparin (19) reduced 
the incidence of CVC-associated thrombosis in patients with 
cancer in randomized controlled trials. Since then, conflicting 
data have been reported for prophylactic anticoagulation from 
randomized controlled trials (20, 21). More recently, a negative 
report on warfarin thrombopropylaxis was published (22); there-
fore, a confirmative study for prophylaxis of thrombotic compli-
cations is required. When a thrombotic occlusion of a CVC oc-
curs, anticoagulation therapy is occasionally available as a sal-
vage therapy instead of catheter removal (23, 24). In our study, 
two cases with thrombotic occlusion were resolved through an-
ticoagulation therapy (urokinase or heparin flushing) without 
removing the catheter. The thrombosis incidence rate tended to 
be more frequent (12.5%, 3 cases) in patients with PICCs than 
CPs or SVCs, but it was not a significant difference, which may 
have been due to the small number of patients enrolled. This 
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Fig. 1. Differences of the catheter life spans according to type of cancer (A) and catheter (B). 
Solid malignancy
Hematologiac malignancy
P=0.002
Median 64 vs 32 days
CP
PICC
SVC
P=0.000
Median 269 vs 37 vs 21 days
A BKim HJ, et al.  •  Central Venous Catheterization in Patients with Cancer
1752   http://jkms.org DOI: 10.3346/jkms.2010.25.12.1748
trend may have resulted from the small lumen of the PICC (25); 
therefore, we should avoid the use of small lumen PICCs.
  Unexpectedly, catheter tip migration was a more frequent 
complication in PICCs (8 cases, 33.3%) than in SVCs or CPs, 
which resulted in a decreased PICC life span (median life span, 
37 days). The PICCs were inserted mid-arm with USG in both 
hospitalized patients and outpatients in our study. The mid-arm 
insertion site may have resulted in tip migration with arm mo-
tion; therefore, PICCs should be fixed well and patients, espe-
cially outpatients, need to be educated (26, 27).  
  We found no catheter-related immediate-onset complications, 
such as a hemothorax or pneumothorax, excluding bleeding. 
Most cases were performed by an expert interventional radiolo-
gist using USG or fluoroscopic guidance, which may have re-
sulted in this finding. Although, a study has reported that USG 
is not beneficial for reducing catheter-related complication (2), 
the finding that we had no catheter-related immediate-onset 
complications, excluding minor bleeding, supports the use of 
an image-guided procedure. Therefore, it is optimal to insert 
catheters using USG or fluoroscopic guidance rather than a 
blind approach to reduce the immediate-onset complication 
rate. However, bleeding is possible in patients with coagulopa-
thy, which needs to be prevented.  
  The median catheter life span was 46 days, and the CP was 
useful for the long term (median 269 days); however, the medi-
an life span of the PICC was 37 days, which was shorter than ex-
pected. A high complication rate, especially tip migration, may 
have contributed to this finding. Additionally, a longer-term use 
of catheters occurred in patients with a solid malignancy than 
hematologic malignancy. Patients with a solid malignancy un-
derwent a CP rather than another catheter type due to sched-
uled, intermittent long-term chemotherapy. Therefore, the CP 
was considered an effective tool for long-term use in patients 
with cancer.
  Some limitations were imposed, including the small number 
of patients; the study was non-randomized and observational, 
and permitted repeated indwelling in the same patient. How-
ever, the main findings were that the major catheter-related com-
plication was infection, which occurred more frequently in young 
patients or those who received a CP; immediate CVC-related 
complications were very rare; and malpositioning or migration 
of the catheter tip was more frequent with a PICC than the oth-
ers and this contributed to the finding that a PICC could not be 
maintained for a long duration. 
  In conclusion, the major problems related to CVCs were in-
fection, thrombosis, and malpositioning or migration of the tip. 
Unexpectedly, a PICC could not be maintained for a long dura-
tion, due mainly to malpositioning or migration. Although the 
use of CPs resulted in a higher infection rate than the others, a 
CP was an effective tool for long-term use in patients with can-
cer. In addition, the insertion of CVCs with the image guidance 
is beneficial and the fixation of tip is important for the manage-
ment of PICC. However the best choice of catheter type is essen-
tial for each patient. A further prospective randomized study 
with central catheters in patients with cancer to investigate the 
complication rate and safety of CVCs is warranted. 
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